FDA Clears First Drug To Treat Phenylketonuria
This article was originally published in The Pink Sheet Daily
Executive Summary
BioMarin estimates Kuvan revenue of $57,000 per patient per year.
You may also be interested in...
BioMarin Tightens Loose Rivets On Bridge To Wider PKU Market
Firm corrects bad numbers for Kuvan new-patient starts ahead of early results with second – and maybe bigger – market player, PEG-PAL
BioMarin Tightens Loose Rivets On Bridge To Wider PKU Market
Firm corrects bad numbers for Kuvan new-patient starts ahead of early results with second – and maybe bigger – market player, PEG-PAL
BioMarin Takes Steps To Drive Kuvan Uptake
Ultra-orphan PKU therapy touted through registry, free trials and clinic-based town hall meetings.